2021 – 2023

  • We successfully commercialized 7 biosimilars: Romiplostim, Teriparatide, Denosumab, Adalimumab, Cetuximab, Bevacizumab and Ranibizumab.
  • We delivered GMP material for 4 Phase I clinical trials, including monoclonal antibodies and complex multi-specific proteins.
  • We established a 2000L fed-batch manufacturing facility for clinical and commercial use.